Odonate Therapeutics Announces Discontinuation of Development of Tesetaxel
22 Março 2021 - 9:00AM
Business Wire
Following feedback from the U.S. Food and Drug Administration
(FDA) in a pre-New Drug Application meeting, Odonate Therapeutics,
Inc. (NASDAQ: ODT) has concluded that the clinical data package for
tesetaxel is unlikely to support FDA approval. Therefore, Odonate
is discontinuing the development of tesetaxel and will wind down
the operations of the Company. The Company will work with clinical
sites to transition patients in ongoing tesetaxel clinical studies
to appropriate alternative therapies.
“We thank the investigators, study team personnel, and
especially the patients and their caregivers for their endeavors to
improve treatments for patients with breast cancer,” said Kevin
Tang, Chief Executive Officer of Odonate.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210322005211/en/
Odonate Therapeutics, Inc. Michael Hearne Chief Financial
Officer (332) 208-7611 mhearne@odonate.com
Odonate Therapeutics (NASDAQ:ODT)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Odonate Therapeutics (NASDAQ:ODT)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
Notícias em tempo-real sobre Odonate Therapeutics Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Odonate Therapeutics, Inc.